| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Merck & Company Inc. | Gefapixant | Chronic cough | NDA Filing | Ongoing | Oral | Respiratory |
| Merck & Company Inc. | JNJ-0953 (CD388) - (ANCHOR) | Seasonal Influenza | Phase 3 | Ongoing | Intramuscular | Respiratory |
| Merck & Company Inc. | Islatravir (MK-8591D) and Lenacapavir - (ISLEND) | Human immunodeficiency virus (HIV) | Phase 3 | Ongoing | Oral | Anti-HIV |
| Merck & Company Inc. | Enlicitide decanoate - (CORALreef AddOn) | Hypercholesterolemia | Phase 3 | Data Released | Intramuscular | Cardiology |
| Merck & Company Inc. | Datopotamab Deruxtecan + KEYTRUDA - (TROPION-Lung07) | Metastatic non-small cell lung cancer (NSCLC) | Phase 3 | Ongoing | Intravenous | Oncology |
| Merck & Company Inc. | Islatravir (MK-8591-022) - (IMPOWER 22) | HIV | Phase 3 | Oral | Anti-HIV | |
| Merck & Company Inc. | Islatravir (MK-8591-024) - (IMPOWER 24) | HIV | Phase 3 | Oral | Anti-HIV | |
| Merck & Company Inc. | ILLUMINATE SWITCH B (doravirine/islatravir) | HIV-1 | Phase 3 | oral | Anti-HIV |